Cargando…

Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas

Despite recent advances in the field, treatment options for metastatic soft tissue sarcoma patients are limited. Eribulin, an antimitotic derived from the natural marine sponge product halichondrin B, is currently approved for the treatment of metastatic breast cancer. Following the promising activi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noujaim, Jonathan, Alam, Salma, Thway, Khin, Jones, Robin Lewis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027783/ https://www.ncbi.nlm.nih.gov/pubmed/27688604 http://dx.doi.org/10.4103/0971-5851.190359

Ejemplares similares

Advances in the treatment of soft tissue sarcoma: focus on eribulin
por: Koliou, Panagiotis, et al.
Publicado: (2018)

Efficacy of Eribulin in Soft Tissue Sarcomas
por: Phillips, Edward, et al.
Publicado: (2022)

Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas
por: Merry, Eve, et al.
Publicado: (2021)

The Extracellular Matrix in Soft Tissue Sarcomas: Pathobiology and Cellular Signalling
por: Pankova, Valeriya, et al.
Publicado: (2021)

Differences in the efficacy and safety of eribulin in patients with soft tissue sarcoma by histological subtype and treatment line
por: Nakano, Kenji, et al.
Publicado: (2021)

Current Status and Future Directions of Immunotherapies in Soft Tissue Sarcomas
por: Kerrison, William G. J., et al.
Publicado: (2022)

Eribulin mesylate in the treatment of metastatic breast cancer
por: Jain, Sarika, et al.
Publicado: (2012)

Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy
por: Noujaim, Jonathan, et al.
Publicado: (2015)

Eribulin in the management of inoperable soft-tissue sarcoma: patient selection and survival
por: Thomas, Colin, et al.
Publicado: (2016)

Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma(†)
por: Kawai, Akira, et al.
Publicado: (2017)

Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells
por: Thway, Khin, et al.
Publicado: (2016)

Eribulin mesylate exerts antitumor effects via CD103
por: Oya, Kazumasa, et al.
Publicado: (2023)

Dermatofibrosarcoma protuberans: from translocation to targeted therapy
por: Noujaim, Jonathan, et al.
Publicado: (2015)

Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin
por: Kawai, Akira, et al.
Publicado: (2017)

Eribulin as a first-line treatment for soft tissue sarcoma patients with contraindications for doxorubicin
por: Tsuchihashi, Kenji, et al.
Publicado: (2020)

The spectrum of EWSR1-rearranged neoplasms at a tertiary sarcoma centre; assessing 772 tumour specimens and the value of current ancillary molecular diagnostic modalities
por: Noujaim, Jonathan, et al.
Publicado: (2017)

Eribulin mesylate in patients with refractory cancers: a Phase I study
por: Mukohara, Toru, et al.
Publicado: (2011)

Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function
por: Tan, Antoinette R., et al.
Publicado: (2015)

Pazopanib in advanced soft tissue sarcomas
por: Lee, Alex T. J., et al.
Publicado: (2019)

Combination of eribulin plus AKT inhibitor evokes synergistic cytotoxicity in soft tissue sarcoma cells
por: Hayasaka, Naotaka, et al.
Publicado: (2019)

Pneumothorax as an Adverse Event in Patients with Lung Metastasis of Soft Tissue Sarcoma under Eribulin Treatment
por: Takada, Kohichi, et al.
Publicado: (2019)

Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors
por: Koczywas, M, et al.
Publicado: (2014)

Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study
por: Kawai, Akira, et al.
Publicado: (2022)

Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer
por: Muñoz-Couselo, Eva, et al.
Publicado: (2011)

Eribulin Mesylate Targets Human Telomerase Reverse Transcriptase in Ovarian Cancer Cells
por: Yamaguchi, Satoko, et al.
Publicado: (2014)

Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective
por: Yuan, Peng, et al.
Publicado: (2021)

Myoepithelial Carcinoma of the Paracecal Mesentery: Aggressive Behavior of a Rare Neoplasm at an Unusual Anatomic Site
por: Thway, Khin, et al.
Publicado: (2017)

Foreign Body Granulomas Induced by Intramuscular Leuprorelin Acetate Injection for Prostate Cancer: Clinical Mimics of Soft Tissue Sarcoma
por: Thway, Khin, et al.
Publicado: (2015)

Efficacy of Eribulin Plus Gemcitabine Combination in L-Sarcomas
por: López-Álvarez, María, et al.
Publicado: (2022)

Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry
por: Milighetti, Martina, et al.
Publicado: (2021)

First line palliative chemotherapy in elderly patients with advanced soft tissue sarcoma
por: Yousaf, Nadia, et al.
Publicado: (2015)

Does the Use of Peripheral Immune-Related Markers Indicate Whether to Administer Pazopanib, Trabectedin, or Eribulin to Advanced Soft Tissue Sarcoma Patients?
por: Shimada, Eijiro, et al.
Publicado: (2021)

Eribulin Mesylate in Pretreated Breast Cancer Patients: A Multicenter Retrospective Observational Study
por: Gamucci, Teresa, et al.
Publicado: (2014)

Eribulin Mesylate-related Multifocal Demyelinating Neuropathy with Myokymia in a Breast Cancer Patient
por: Tsunogae, Marie, et al.
Publicado: (2021)

Eribulin mesylate induces bone mass loss by promoting osteoclastic bone resorption in mice
por: Ishizaka, Takahiro, et al.
Publicado: (2023)

Soft Tissue Myoepithelial Carcinoma Metastatic to the Cecum: Highlighting an Unusual Metastatic Pattern and the Need for Diagnostic Awareness
por: Mourtzoukou, Despoina, et al.
Publicado: (2016)

Histopathological Diagnostic Discrepancies in Soft Tissue Tumours Referred to a Specialist Centre
por: Thway, Khin, et al.
Publicado: (2009)

Interim results of a real-world observational study of eribulin in soft tissue sarcoma including rare subtypes
por: Kobayashi, Eisuke, et al.
Publicado: (2019)

The proteomic landscape of soft tissue sarcomas
por: Burns, Jessica, et al.
Publicado: (2023)

Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib
por: Rajendra, Rajeev, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_smrp0qg8egnborthtsma97nipl